Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224568 · ClinicalTrials.gov registry record · Phase 1
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT07224568 is a Phase 1 study that has not yet begun recruiting, run by Seattle Children's Hospital. The registered enrollment target is 21 participants.
The verdict
NCT07224568, a Phase 1 study, has not yet begun recruiting, sponsored by Seattle Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21 as well as the inducible caspase 9 (iC9) suicide gene (SC-CAR.GPC3xIL15.21 T cells). An adult participant meeting all eligibility criteria and meeting none of the exclusion criteria will have a blood sample collected, which will be used to bioengineer the CAR T cells targeting their tumor.
Interventions
- BIOLOGICAL SC-CAR.GPC3xIL15.21 CAR T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2045-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224568
The ClinicalTrials.gov registry entry for NCT07224568 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SC-CAR.GPC3xIL15.21 CAR T cells is the first listed.
NCT07224568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224568 about?
NCT07224568 is a clinical study titled "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors". This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood m...
What is the current status of trial NCT07224568?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2026-04-01. Estimated completion is 2045-08.
What interventions are being tested in trial NCT07224568?
The interventions under investigation include: SC-CAR.GPC3xIL15.21 CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07224568?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.